Apomorphine is a dopamine agonist used in the treatment of some motor and non-motor complications during Parkinson's disease, which could be administered as an intermittent or continuous infusion. Although apomorphine treatment has been shown to be effective on motor fluctuations and dyskinesias, there is no sufficient consensus regarding the administration of apomorphine test or infusion, and the management of the treatment. In this review, our aim is to create a "treatment management guideline," which includes recommendations for the use of apomorphine in the clinical practice, and to discuss the problems encountered in both intermittent and continuous infusion applications, in the light of the literature
Six patients with Parkinson's disease and refractory motor fluctuations, with severe subcutaneous (s...
Levodopa-induced motor fluctuations (MF) is a disabling complication of Parkinson's disease (PD) and...
Subcutaneous continuous infusion of apomorphine has been shown to effectively reduce off-time and dy...
Apomorphine is a dopamine agonist used in the treatment of some motor and non-motor complications du...
ABSTRACT Optimizing idiopathic Parkinson's disease treatment is a challenging, multifaceted and cont...
Apomorphine is a dopamine agonist administered subcutaneously as intermittent infections or in a con...
Apomorphine is a potent, nonselective, direct-acting dopamine-receptor agonist. Given subcutaneously...
Extensive published evidence supports the use of subcutaneously-administered apomorphine as an effec...
The clinical utility of long-term oral levodopa therapy in Parkinson disease (PD) is often limited b...
The intermittent subcutaneous injection of apomorphine is highly effective in the management of moto...
Background Subcutaneous apomorphine infusion is a clinically established therapy for patients with P...
Background Subcutaneous apomorphine infusion is a clinically established therapy for patients with P...
International audienceThe present paper consists of a comprehensive review of the literature on apom...
OBJECTIVES: Despite the recent introduction of new peroral drugs as well as neurosurgical methods fo...
Continuous infusion of levodopa or apomorphine provide constant dopaminergic stimulations are good a...
Six patients with Parkinson's disease and refractory motor fluctuations, with severe subcutaneous (s...
Levodopa-induced motor fluctuations (MF) is a disabling complication of Parkinson's disease (PD) and...
Subcutaneous continuous infusion of apomorphine has been shown to effectively reduce off-time and dy...
Apomorphine is a dopamine agonist used in the treatment of some motor and non-motor complications du...
ABSTRACT Optimizing idiopathic Parkinson's disease treatment is a challenging, multifaceted and cont...
Apomorphine is a dopamine agonist administered subcutaneously as intermittent infections or in a con...
Apomorphine is a potent, nonselective, direct-acting dopamine-receptor agonist. Given subcutaneously...
Extensive published evidence supports the use of subcutaneously-administered apomorphine as an effec...
The clinical utility of long-term oral levodopa therapy in Parkinson disease (PD) is often limited b...
The intermittent subcutaneous injection of apomorphine is highly effective in the management of moto...
Background Subcutaneous apomorphine infusion is a clinically established therapy for patients with P...
Background Subcutaneous apomorphine infusion is a clinically established therapy for patients with P...
International audienceThe present paper consists of a comprehensive review of the literature on apom...
OBJECTIVES: Despite the recent introduction of new peroral drugs as well as neurosurgical methods fo...
Continuous infusion of levodopa or apomorphine provide constant dopaminergic stimulations are good a...
Six patients with Parkinson's disease and refractory motor fluctuations, with severe subcutaneous (s...
Levodopa-induced motor fluctuations (MF) is a disabling complication of Parkinson's disease (PD) and...
Subcutaneous continuous infusion of apomorphine has been shown to effectively reduce off-time and dy...